酒精性肝病患者肠道微生态变化研究进展*

doi:10.3969/j.issn.1672-5069.2022.05.038

Abstract

Abstract: Objective Alcoholic liver disease (ALD) is one of the major causes of death related to liver disease over the world. The alcohol consumption and the related diseases have become a global health burden. There is growing evidence of strong correlation of intestinal microbiome disorders to liver diseases. The translocation of bacteria and their products caused by the destruction of the intestinal barrier is the key factor to lead to complications of liver diseases. In recent years, many new biomarkers and therapeutic targets are the hotspots in the field of ALD studies.

Key words: Alcoholic liver diseases, Intestinal microbiome, Pathogenesis, Markers

Zhang Gaixia, Chen Haizhen, Huang Jing. Intestinal microecology in patients with alcoholic liver diseases[J]. Journal of Practical Hepatology, 2022, 25(5): 757-760.

References

[1]Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers, 2018, 4(1): 16.
[2]Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut, 2016, 65(12): 2035-2044.
[3]Sarin SK, Pande A, Schnabl B. Microbiome as a therapeutic target in alcohol-related liver disease. J Hepatol, 2019, 70(2): 260-272.
[4]Mutlu EA, Gillevet PM, Rangwala H, et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol, 2012, 302(9): G966-978.
[5]Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology, 2011, 53(1): 96-105.
[6]Bull-Otterson L, Feng W, Kirpich I, et al. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One, 2013, 8(1): e53028.
[7]Bluemel S, Wang L, Kuelbs C, et al. Intestinal and hepatic microbiota changes associated with chronic ethanol administration in mice. Gut Microbes, 2020, 11(3): 265-275.
[8]Lowe PP, Gyongyosi B, Satishchandran A, et al. Alcohol-related changes in the intestinal microbiome influence neutrophil infiltration, inflammation and steatosis in early alcoholic hepatitis in mice. PLoS One, 2017, 12(3): e0174544.
[9]Seo B, Jeon K, Moon S, et al. Roseburia spp. abundance associates with alcohol consumption in humans and its administration ameliorates alcoholic fatty liver in mice. Cell Host Microbe, 2020, 27(1): 25-40,e26.
[10] Llopis M, Cassard AM, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut, 2016, 65(5): 830-839.
[11] Engen PA, Green SJ, Voigt RM, et al. The gastrointestinal microbiome: Alcohol effects on the composition of intestinal microbiota. Alcohol Res, 2015, 37(2): 223-236.
[12] 栗红江, 何福亮, 陈来印. 酒精性肝病患者血清LP、LPO、NOS水平和肠道菌群分布变化分析. 实用肝脏病杂志, 2020, 23(4): 536-539.
[13] 延喜胜, 李伟, 王剑. 酒精性肝病患者血清细胞因子水平和肠道菌群分布变化研究. 实用肝脏病杂志, 2019, 22(4): 518-521.
[14] Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology, 2014, 146(6): 1513-1524.
[15] Chen P, Torralba M, Tan J, et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology, 2015, 148(1): 203-214 e216.
[16] Bjorkhaug ST, Aanes H, Neupane SP, et al. Characterization of gut microbiota composition and functions in patients with chronic alcohol overconsumption. Gut Microbes, 2019, 10(6): 663-675.
[17] Hartmann P, Hochrath K, Horvath A, et al. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology, 2018, 67(6): 2150-2166.
[18] Chu H, Duan Y, Lang S, et al. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J Hepatol, 2020, 72(3): 391-400.
[19] Yang AM, Inamine T, Hochrath K, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest, 2017, 127(7): 2829-2841.
[20] Jiang L, Lang S, Duan Y, et al. Intestinal virome in patients with alcoholic hepatitis. Hepatology, 2020, 72(6): 2182-2196.
[21] Zuo T, Lu XJ, Zhang Y, et al. Gut mucosal virome alterations in ulcerative colitis. Gut, 2019, 68(7): 1169-1179.
[22] Bajaj JS. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol, 2019, 16(4): 235-246.
[23] Paone P, Cani PD. Mucus barrier, mucins and gut microbiota: the expected slimy partners? Gut, 2020, 69(12): 2232-2243.
[24] Hartmann P, Chen P, Wang HJ, et al. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology, 2013, 58(1): 108-119.
[25] Rao RK. Acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayer. Alcohol Clin Exp Res, 1998, 22(8): 1724-1730.
[26] Abdelmegeed MA, Banerjee A, Jang S, et al. CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis. Free Radic Biol Med, 2013, 65: 1238-1245.
[27] Chen P, Starkel P, Turner JR, et al. Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology, 2015, 61(3): 883-894.
[28] Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol, 2018, 15(7): 397-411.
[29] Bala S, Csak T, Saha B, et al. The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis. J Hepatol, 2016, 64(6): 1378-1387.
[30] Shao T, Zhao C, Li F, et al. Intestinal HIF-1alpha deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction. J Hepatol, 2018, 69(4): 886-895.
[31] Wang Y, Liu Y, Sidhu A, et al. Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury. Am J Physiol Gastrointest Liver Physiol, 2012, 303(1): G32-41.
[32] Li HS, Zhou YN, Li L, et al. HIF-1alpha protects against oxidative stress by directly targeting mitochondria. Redox Biol, 2019, 25: 101109.
[33] Duan Y, Llorente C, Lang S, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature, 2019, 575(7783): 505-511.
[34] Zhou R, Llorente C, Cao J, et al. Deficiency of intestinal alpha1-2-fucosylation exacerbates ethanol-induced liver disease in mice. Alcohol Clin Exp Res, 2020, 44(9): 1842-1851.
[35] Wang L, Fouts DE, Starkel P, et al. Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation. Cell Host Microbe, 2016, 19(2): 227-239.
[36] Hendrikx T, Duan Y, Wang Y, et al. Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut, 2019, 68(8): 1504-1515.
[37] Wrzosek L, Ciocan D, Hugot C, et al. Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury. Gut, 2021, 70(7): 1299-1308.
[38] Lang S, Duan Y, Liu J, et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology, 2020, 71(2): 522-538.

Intestinal microecology in patients with alcoholic liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Luo Nan, Li Rongkuan. Spontaneous bacterial peritonitis in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(5): 616-619.
[2]	Jin Panpan, Zhang Lingyi. PIVKA-II: a new biological marker in diagnosis of patients with hepatitis B-related hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(4): 605-608.
[3]	Guo Yuecheng, Lu Lungen. Diagnosis and management of liver fibrosis [J]. Journal of Practical Hepatology, 2022, 25(3): 305-308.
[4]	Lin Ning, Kong Ming, Duan Zhongping. Pathogenesis of sarcopenia in liver diseases [J]. Journal of Practical Hepatology, 2022, 25(2): 301-304.
[5]	Feng Yu, Du Zhenyuan, Li Yanbin, et al. Serum IL-17 levels and single nucleotide polymorphism of its gene at -197A/G locus in patients with alcoholic liver diseases [J]. Journal of Practical Hepatology, 2022, 25(1): 58-61.
[6]	Liu Lixia, Lin Yingyuan, Li Huamin, et al. Comparative study on the clinical efficacy of lorazepam and oxazepam in treatment of patients with alcoholic liver diseases and alcohol withdrawal syndrome [J]. Journal of Practical Hepatology, 2021, 24(5): 709-712.
[7]	Liu Zhen,Pan Guangdong,Zhou Zheng,et al. Expression of copb2 gene incancerous tissues in patients with hepatocellular carcinoma and its relationship with prognosis [J]. Journal of Practical Hepatology, 2021, 24(1): 115-118.
[8]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[9]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[10]	Wang Haifang, Yang Dawei, Jia Bei. Impact of nutrition support and medusa administration on liver function, erythrocyte and platelet parameters in patients with alcoholic liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 381-384.
[11]	Zhao Xitai, Nie Qinghe. Serum microRNA in diagnosis of patients with hepatocellular carcinoma and methodological progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 297-300.
[12]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[13]	Guo Baona, Zhan Yutao.. Clinical features of alcoholic liver diseases:An analysis of 79 cases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 877-880.
[14]	Cui Ruibing, Yan Ming.. Etiology of ascites:what’s going on [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 657-660.
[15]	Li Yue, Ding Huiguo.. Current diagnosis and treatment of chylous ascites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 665-668.